Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis

Last updated: October 8, 2019
Sponsor: Eurofarma Laboratorios S.A.
Overall Status: Trial Not Available

Phase

3

Condition

Rhinitis, Allergic, Perennial

Common Cold

Nasal Obstruction

Treatment

N/A

Clinical Study ID

NCT02988778
EF149
  • Ages 12-90
  • All Genders

Study Summary

This study is to evaluate non inferiority of Eurofarma budesonide nasal spray x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 12

  2. History of allergic persistent rhinitis moderate to severe at least 2 years

  3. Proved allergic using PRICK or RAST test

  4. Nasal symptoms (NIS) > 3 and nasal obstruction >1

  5. Indication of nasal corticosteroids use

  6. Washout of nasal corticosteroids for 14 days

  7. ICF

Exclusion

Exclusion Criteria:

  1. Other types of rhinitis

  2. Asthma non controlled

  3. Use of oral/injectable corticoids 30 days before screening

  4. patients not eligible to complete diaries

  5. patients with allergy to any substance of medicines

  6. non controlled disease

Study Design

Study Start date:
October 08, 2019
Estimated Completion Date:
October 08, 2019

Study Description

Budesonide is a medicine already very used and registered about 20 years. Eurofarma has the intention to collect more data about safety and efficacy and present them to local authority.

This study was draw to treat patients with persistent rhinitis moderate to severe in sites located locally in Brazil.

Connect with a study center

  • Alexandra Dumont

    Campinas,
    Brazil

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.